Volume 155, Issue 3, Pages (March 1996)

Slides:

Advertisements

Similar presentations

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer.

Advertisements

Evidence for Autosomal Dominant Inheritance of Prostate Cancer

Volume 187, Issue 6, Pages (June 2012)

Volume 62, Issue 3, Pages (September 2012)

Volume 72, Issue 1, Pages (July 2017)

MP60-03 PROSTATE CANCER IN THE ELDERLY

The PSA Era is not Over for Prostate Cancer

Volume 105, Issue 3, Pages (March 1994)

Volume 66, Issue 2, Pages (August 2014)

Volume 195, Issue 5, Pages (May 2016)

Volume 50, Issue 1, Pages (July 2006)

2327 PROSTATE CANCER STAGE, GRADE AND POSITIVE MARGIN RATE IN MEN WITH PSA ≥ 1 ng/ml UNDERGOING RADICAL PROSTATECTOMY: POPULATION DATA ANALYSIS Sergey.

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Volume 4, Issue 5, Pages (September 2017)

Volume 58, Issue 5, Pages (November 2010)

Volume 49, Issue 2, Pages (February 2006)

Volume 199, Issue 1, Pages (January 2018)

Volume 53, Issue 5, Pages (May 2008)

Volume 51, Issue 3, Pages (March 2007)

Volume 52, Issue 4, Pages (October 2007)

Volume 183, Issue 3, Pages (March 2010)

Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Volume 199, Issue 1, Pages (January 2018)

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 62, Issue 1, Pages (July 2012)

Volume 184, Issue 4, Pages (October 2010)

Volume 67, Issue 3, Pages (March 2015)

Volume 71, Issue 5, Pages (May 2017)

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer.

Volume 185, Issue 2, Pages (February 2011)

Luis Martínez-Piñeiro European Urology Supplements

The PSA Era is not Over for Prostate Cancer

Volume 53, Issue 2, Pages (February 2008)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Volume 58, Issue 1, Pages 1-7 (July 2010)

LESLIE M. RAINWATER, M.D., WILLIAM R. MORGAN, M.D.

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Risk Factors for the Development of Bone Metastases in Prostate Cancer

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

Volume 72, Issue 1, Pages (July 2017)

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Highlighting Unmet Needs: Real Patients, Difficult Choices

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Evidence for Autosomal Dominant Inheritance of Prostate Cancer

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Presentation transcript:

Volume 155, Issue 3, Pages 821-826 (March 1996) Prostate Specific Antigen Detected Prostate Cancer (Clinical Stage T1C): An Interim Analysis Seth E. Lerner, Thomas M. Seay, Michael L. Blute, Erik J. Bergstralh, David Barrett, Horst Zincke The Journal of Urology Volume 155, Issue 3, Pages 821-826 (March 1996) DOI: 10.1016/S0022-5347(01)66317-1 Copyright © 1996 American Urological Association, Inc. Terms and Conditions

Figure 1 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimate for 257 patients with clinical stage T1c prostate cancer after radical prostatectomy (1987 to 1991) with or without adjuvant treatment. Numbers above lines represent number of patients at risk. The Journal of Urology 1996 155, 821-826DOI: (10.1016/S0022-5347(01)66317-1) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

Figure 2 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimates for 257 patients with clinical stage T1c prostate cancer treated with radical prostatectomy with or without adjuvant therapy, according to pathological stage. Numbers above lines represent number of patients at risk. The Journal of Urology 1996 155, 821-826DOI: (10.1016/S0022-5347(01)66317-1) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

Figure 3 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimates for 208 patients with clinical stage T1c prostate cancer treated with radical prostatectomy without adjuvant therapy, according to preoperative serum PSA (ng./ml.). Numbers above lines represent number of patients at risk. The Journal of Urology 1996 155, 821-826DOI: (10.1016/S0022-5347(01)66317-1) Copyright © 1996 American Urological Association, Inc. Terms and Conditions

Figure 4 Kaplan-Meier progression-free (local/systemic/PSA greater than 0.2 ng./ml.) survival estimates for 1,679 patients after radical prostatectomy without adjuvant therapy for stage T2b/c or less prostate cancer according to clinical stage. Numbers above lines represent number of patients at risk. The Journal of Urology 1996 155, 821-826DOI: (10.1016/S0022-5347(01)66317-1) Copyright © 1996 American Urological Association, Inc. Terms and Conditions